Blood pressure, heart rate, plasma epinephrine, norepinephrine and vasopressin concentrations increased slightly in response to laryngoscopy and intubation, all returning to or below baseline 5 min later with no change in angiotensin converting enzyme activity in normotensive patients.

No abstract

No abstract

No abstract

Ge liş Ta ri hi/Re cei ved: 18.05.2015 Ka bul Ta ri hi/Ac cep ted: 20.05.2015 © Üroonkoloji Bülteni, Ga le nos Ya yı ne vi ta ra fın dan ba sıl mış tır./ © Bulletin of Urooncology, Pub lis hed by Ga le nos Pub lis hing.Objective: In the cancer treatment, protein kinase inhibitors targeted at markers such as Her-2/neu (c-erbB2) and c-kit (CD117) are successful approaches. In this study, the expression of c-erbB2 and CD117 in normal prostate tissue as well as with low, moderate and high risk acinar adenocarcinoma of prostate with no androgen-suppression therapy, and, metastatic adenocarcinoma of prostate was investigated and the expression of androgen receptor (AR) was compared with c-erbB2 and CD117. Materials and Methods: Hematoxylene-eosine sections of 80 patients diagnosed with acinar adenocarcinoma of prostate and 20 patients diagnosed as benign prostate tissue between 2005-2013 years were re-evaluated. Prostatic adenocarcinoma cases were re-classified as low, moderate and high risk (according to D'Amico risk classification) and metastatic ones into groups with 20 specimens. Immuno-histochemistry studies with AR, c-erbB2 and CD117 were performed in all groups. Results: There was no staining with c-erbB2 and CD117 in benign prostate tissues. 15/80 (18.75%) and 32/80 (40%) of the prostatic adenocarcinomas stained positively with c-erbB2 and CD117 respectively. For both markers, the highest proportion (35%) of positive staining was found in the metastatic carcinoma groups with c-erbB2 (n=7/20, p=0.010 for all study groups) and 65% staining with CD117 (n=13/20, p=0.00004 for all study groups). All groups showed AR staining; prostatic adenocarcinoma. AR positivity was highest in the metastatic group (85%, 17/20, p=0.010). Prevalence of AR positivity between groups was similar to that of c-erbB2 and CD117. Conclusion: The expressions of c-erbB2, CD117 and AR increase at significant level in cases of metastatic prostatic adenocarcinoma that hasn't receive preoperative androgen suppression therapy. This result indicates that the increased expression levels of c-erbB2, CD117 and AR is related with a higher degree of malignancy and therapeutic agents against to c-erbB2 and CD117 could be combined with anti-androgenic agents in planning of treatment.Amaç: Kanser tedavisinde c-erbB2 (c-erbB2) ve c-kit (CD117) gibi belirteçleri hedef alan protein kinaz inhibitörleri günümüzde başarı sağlanmış yaklaşımlardır. Bu çalışmada, benign prostat dokusu ile preoperatif androjen baskılayıcı tedavi almamış, düşük, orta ve yüksek riskli prostatik asiner adenokarsinomlarda ve metastatik prostatik adenokarsinomda terapötik hedefi olan bu belirteçlerin ifade sıklığı araştırılmış ve farklı tümör kategorilerinde androjen reseptör (AR) ekspresyon sıklığı c-erbB2 ve CD117'nin ekspresyon sıklığı ile karşılaştırılmıştır. Gereç ve Yöntem: 2005-2013 yılları arasında benign prostat dokusu tanılı 20 olgu ve prostatik asiner adenokarsinom tanılı 80 olgu çalışmaya alındı. Prostatik adenokarsinom olguları 20'şerli gruplar halinde düşük riskli, orta ri...